The Zacks Analyst Blog Highlights: Bayer, Novartis, Pfizer, Actelion and Abbott Labs

   The Zacks Analyst Blog Highlights: Bayer, Novartis, Pfizer, Actelion and
                                 Abbott Labs

PR Newswire

CHICAGO, Aug. 22, 2013

CHICAGO, Aug. 22, 2013 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include  the Bayer (OTC:BAYRY-Free
Report), Novartis (NYSE:NVS-Free Report), Pfizer Inc. (NYSE:PFE-Free Report),
Actelion Ltd. (OTC:ALIOF-Free Report) and Abbott Labs (NYSE:ABT-Free Report).


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Good News for Bayer from Japan

The HealthCare segment of Bayer (OTC:BAYRY-Free Report) recently announced
that the Ministry of Health, Labor and Welfare (MHLW) in Japan approved
Stivarga for the treatment of patients suffering from gastrointestinal stromal
tumor (GIST) who have progressed following prior systemic cancer therapy.

The drug's approval was based on positive results from Bayer's phase III GRID
(GIST – Regorafenib In Progressive Disease) study. Bayer enrolled 199 patients
for the study suffering from metastatic and/or unresectable GIST and whose
disease has progressed in spite of being previously treated with Novartis'
(NYSE:NVS-Free Report) Gleevec (imatinib mesylate) and Pfizer Inc.'s
(NYSE:PFE-Free Report) Sutent (sunitinib malate).

Results from the study revealed that patients treated with Stivarga showed a
statistically significant improvement in progression-free survival (PFS) in
comparison to patients under placebo. Stivarga is also approved in the U.S.
for the GIST indication.

We note that this is Stivarga's second approval in Japan. In Mar 2013, the
drug was approved for the treatment of patients suffering from unresectable,
advanced/recurrent colorectal cancer (CRC).

Stivarga is already approved in the U.S. for treating patients suffering from
metastatic CRC (mCRC), whose disease has progressed even after treatment with
standard drugs. Bayer is also seeking EU approval of Stivarga for the
treatment of mCRC. In Jul 2013, Bayer received a positive opinion from the
Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMA) for the approval of Stivarga in the mCRC indication.

A final decision from the EU regulatory authorities on the approval of
Stivarga is expected by Dec 31, 2013. We note that though the European
Commission is not bound to follow the CHMP's decision, it generally does so.
We believe that further market expansion will boost the drug's sales

Bayer presently carries a Zacks Rank #3 (Hold). However, other pharma stocks,
such as Actelion Ltd. (OTC:ALIOF-Free Report), currently look better
positioned with a Zacks Rank #1 (Strong Buy).

Abbott Acquires OptiMedica

Abbott Labs (NYSE:ABT-Free Report) recently announced that it has completed
the previously announced acquisition of privately-held OptiMedica Corporation
for $250 million in cash.

The acquisition was announced in Jul 2013. This acquisition should expand
Abbott Labs' vision care business into the femtosecond laser-assisted cataract
surgery market.

OptiMedica's Catalys Precision Laser System carries a CE mark in the EU and
has been approved in the U.S. as well. This laser system replaces certain
manual steps in cataract surgery with precise, image-guided, femtosecond laser

Hence, the acquisition will further boost the cataract surgery business at
Abbott Labs' which currently account for 60% of total sales of the vision care

Abbott Labs's vision care business was up 2% in the second quarter of 2013
driven by solid cataract sales attributed to strong double-digit growth in the
emerging markets and Tecnis of intraocular lenses (IOL).

Abbott Labs expects further growth in its cataract business to be driven by
several important new product launches in 2013.

Key launches include Tecnis OptiBlue in Japan providing access to the largest
segment of the Japanese market and Tecnis Toric in the U.S. enabling Abbott
Labs to enter the faster growing premium segment of the IOL market.

Further, Abbott Labs expects to launch Tecnis Preloaded IOL in the U.S. in the
second half of 2013 which should propel growth.

Hence, Abbott Labs expects mid-single digit growth (excluding currency
translation impact) in the third quarter of 2013 driven by traction in the
cataract surgery business.

We are impressed by Abbott Lab's efforts to drive growth in its promising
vision care business.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the

Get the full Report on BAYRY - FREE

Get the full Report on NVS - FREE

Get the full Report on PFE - FREE

Get the full Report on ALIOF - FREE

Get the full Report on ABT - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.